Lisata Therapeutics旗下子公司Marea Therapeutics今日宣布,其候选药物Mar002的二期临床试验已顺利完成首例患者给药。Mar002是一款针对肢端肥大症的在研疗法,具有成为同类最佳治疗方案的潜力。
Lisata Therapeutics旗下子公司Marea Therapeutics今日宣布,其候选药物Mar002的二期临床试验已顺利完成首例患者给药。Mar002是一款针对肢端肥大症的在研疗法,具有成为同类最佳治疗方案的潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.